info@biomedres.us   +1 (720) 414-3554   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

“Mas Spec Pen”, The New Future For Cancer Diagnosis: Mini Review

Volume 1 - Issue 4

Bhupendra G Prajapati1* and Sankha Bhattacharya2

  • Author Information Open or Close
    • 1Department of Pharmaceutical Technology, Ganpat University, India
    • 2Department of Pharmaceutics, Rofel Shri GM Bilakhia College of Pharmacy, India

    *Corresponding author: Bhupendra G Prajapati, Associate Professor, Department of Pharmaceutical Technology, Ganpat University, Kherva, Mehsana, Gujarat-384012, India

Received: September 14, 2017;   Published: September 27, 2017

DOI: 10.26717/BJSTR.2017.01.000397

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Our intention is to give an outline and aware about recent innovation called Mas-Spec Pen developed at the University of Texas. This innovation could revolutionize the cancer diagnosis in upcoming days. Jialing Zihanget al. developed this biocompatible and automated device for non-destructive diagnosis of cancerous cells. This device attached with one handheld mass spectrometer. They named it as Mas- Spec Pen. This device could deliver discrete water to diseased tissue to extract biomolecules for cancer diagnosis. They have analyzed this instrument applicability by using it in 253 human patient tissue samples from lung, thyroids, and ovary. With this method, it has become very easy to estimate the potential cancer biomarkers in a form of lipids, metabolites, and proteins. This device could produce 96.3% accuracy in cancer prediction. In histological composition, this device could easily identify cancerous cells within normal cells. This device could also be useful in the diagnosis of residual cancerous cells during open surgery. Nevertheless, this device can be a future for ex vivo and in vivo cancer diagnosis. Finally, we have shown how international media houses responded on this current discovery.

Keywords : MasSpec Pen; Histopathology; Breast Cancer; Lung Cancer; Mass Spectrometry

Abbreviations : PCA: Principal Component Analysis; PDMS: Polydimethylsiloxane; PE: Glycerophosphoetanolamide; PS: Glycerophosphoserines; PI: Glycerophosphoinositol; CL: Cardiolipins

Introduction| Operative Specifications of MasSpec Pen [1]| How the MasSpec Pen works| Media headlines about MasSpec Pen| Conclusion| References|